Shaping the Future of Liver Research and Toxicology
Fully functional iPSC-derived hepatocyte models (Opti-HEP) for generating pre-clinical human data
Recent News
Upcoming Events
Enabling cures for liver disease through highly predictive in vitro modeling
We generate high-quality, phenotypically relevant disease modeled hepatocytes that can be utilized to screen compounds.
Disease Modeling
DefiniGEN's platform technology enables the generation of predictive and phenotypically relevant iPSC-derived human disease models for a wide range of metabolic and liver diseases which can be produced at scale.
Profiling Molecules
Combine our expertise at generating iPSC-derived hepatocyte disease models with our wide panel of bespoke bioassays. We work as partners with your team to design and implement in-house screening of small molecules and advanced genetic therapies, so you can advance your program at speed.
Specialist CRO focused on delivering liver and metabolic disease models
Highly Predictive
Opti-HEPs successfully recapitulate key aspects of disease pathophysiology across a wide-range of conditions that affect different aspects of liver function.
Scalable
DefiniGEN’s proprietary differentiation protocol permits large-scale generation of hepatocyte-like cells with field leading purity and functionality.
Optimized Bioassay Development
Optimized bioassays that can accurately evaluate compound potency, efficacy and delivery.